Mr. Michael Jenkins, President and CEO of The Jenex Corporation, (TSX-V: JEN) (Frankfurt Exchange: JNX) announced today that it has signed an agreement with Competitive Technologies Inc. (AMEX: CTT) to license and commercialize their patented Therapik® product.  CTT will have exclusive rights to license Therapik® in Korea, China, Japan, Taiwan, Australia, Russia, Eastern Europe and India. CTT will have non-exclusive rights in all other countries. Therapik® is a ready-to-market medical device approved to provide relief of the pain, itch and inflammation, resulting from insect stings and bites. The technology is approved by both the US Food and Drug Administration and the Canadian Therapeutic Products Program. Patents in 15 countries, including the United States, Canada, Australia and Europe protect the technology.

Mr. Jenkins said, “This agreement with Competitive Technologies is an important step in establishing foreign market sales and distribution for our Therapik® product, as well as securing low cost manufacturing for our products. Jenex will benefit from CTT’s strong global alliances as we build a recurring revenue stream through our licensees and strengthen shareholder value.”

“Therapik’s ready-to-market status provides a balance in our life science portfolio between early and late stage technologies and presents strong revenue opportunities for CTT going forward,” said Aris D. Despo, CTT’s VP Life Science Business Development. “Therapik’s proven capabilities make it an attractive and exciting addition to our portfolio. We will be offering market opportunities for this technology through licensed manufacturing agreements, and country-specific product distributors.”

“The Jenex agreement is evidence of CTT gaining outstanding technologies from our clients to move into the marketplace in line with our strategic plan for sustainable long term growth,” said John B. Nano, CTT’s President and CEO.

About Jenex Corporation

The Jenex Corporation is a publicly traded medical device research and development company focused on developing unique consumer and healthcare products. Formed in 1999, Jenex is primarily concentrated on the field of thermal therapy technology. Visit Jenex’s website at http://www.jenexcorp.com

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, digital, nano, and physical sciences developed by universities, companies and inventors. The global market for technology transfer services is estimated at $150 billion annually. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT’s website: http://www.competitivetech.net

Direct Inquiries:

Michael Jenkins, The Jenex Corporation                       E-Mail: jenex@sprint.ca

Tel:  (905) 632-3830    Fax:  (905) 632-3774

Competitive Technologies                                             E-Mail:  ctt@competitivetech.net

Johnnie D. Johnson, Strategic IR, Inc.                         E-Mail: jdjohnson@strategic-ir.com

Tel:  (212) 754-6565    Fax:  (212) 754-4333

The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or the contents of this press release.  Certain information included in this press release is forward-looking and is subject to important risks and uncertainties.  The results or events predicted in these statements may differ materially from actual results or events.